BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

Benzinga Newsdesk www.benzinga.com Negative 69.1%

Neg 69.1% Neu 0% Pos 0%

BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.